Asian Penny Stocks To Watch In June 2025

Amid rising geopolitical tensions and fluctuating economic indicators, Asian markets have shown resilience, with investors closely monitoring developments in trade talks and inflation data. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Top 10 Penny Stocks In Asia

Click here to see the full list of 1,164 stocks from our Asian Penny Stocks screener.

Let's uncover some gems from our specialized screener.

ISEC Healthcare (Catalist:40T)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ISEC Healthcare Ltd. is an investment holding company that offers medical care, consultancy, treatment, and surgery services specializing in ophthalmology across Singapore, Malaysia, and Myanmar with a market cap of SGD204.19 million.

Operations: ISEC Healthcare generates its revenue primarily through the provision of medical care, consultancy, treatment, and surgery services in the field of ophthalmology across Singapore, Malaysia, and Myanmar.

Market Cap: SGD204.19M

ISEC Healthcare Ltd. operates with a market cap of SGD204.19 million, primarily generating revenue from ophthalmology services across Singapore, Malaysia, and Myanmar. The company maintains a strong financial position with short-term assets exceeding both short-term and long-term liabilities, while its debt is well covered by operating cash flow. Despite negative earnings growth over the past year and a slight decrease in net profit margins to 17%, ISEC's earnings have grown significantly over the past five years. Recently, ISEC approved a final dividend of 0.7 Singapore cents per share for FY2024 amidst stable shareholder equity without significant dilution.

• Dive into the specifics of ISEC Healthcare here with our thorough balance sheet health report.
• Learn about ISEC Healthcare's historical performance here.

Manila Mining (PSE:MA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Manila Mining Corporation is involved in the mining and exploration of precious metals, ores, and minerals in the Philippines with a market capitalization of approximately ₱2.05 billion.

Operations: Manila Mining Corporation has not reported any revenue segments.

Market Cap: ₱2.05B

Manila Mining Corporation, with a market cap of ₱2.05 billion, remains pre-revenue and faces significant financial challenges. Despite being debt-free and having a cash runway exceeding three years, the company is unprofitable with increasing losses over the past five years. Recent earnings reports indicate minimal revenue and ongoing net losses, while auditors have expressed doubts about its ability to continue as a going concern. The company's short-term assets fall short of covering its liabilities, though long-term liabilities are adequately covered. Its seasoned board and management team provide stability amidst high share price volatility and trading below estimated fair value.

• Navigate through the intricacies of Manila Mining with our comprehensive balance sheet health report here.
• Understand Manila Mining's track record by examining our performance history report.

JBM (Healthcare) (SEHK:2161)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: JBM (Healthcare) Limited is an investment holding company involved in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products across Hong Kong, Macau, Mainland China, and internationally with a market cap of HK$2.32 billion.

Operations: The company's revenue is derived from three main segments: Branded Medicines (HK$272.23 million), Health and Wellness Products (HK$104.61 million), and Proprietary Chinese Medicines (HK$405.45 million).

Market Cap: HK$2.32B

JBM (Healthcare) Limited, with a market cap of HK$2.32 billion, demonstrates strong financial health and growth potential. Its recent earnings report shows an increase in sales to HK$782.29 million and net income rising to HK$197.26 million, reflecting effective brand management strategies across its segments. The company's debt reduction over five years has improved its balance sheet, with short-term assets covering both short- and long-term liabilities comfortably. While the management team is relatively new, the experienced board provides strategic oversight. Recent dividend increases highlight confidence in sustained profitability amidst stable weekly volatility and no shareholder dilution.

• Get an in-depth perspective on JBM (Healthcare)'s performance by reading our balance sheet health report here.
• Learn about JBM (Healthcare)'s future growth trajectory here.

Where To Now?

• Unlock more gems! Our Asian Penny Stocks screener has unearthed 1,161 more companies for you to explore.Click here to unveil our expertly curated list of 1,164 Asian Penny Stocks.
• Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com